Written by Gamal Baheeg Mohamed, Madeha Abdellah Saed, Abdelhakeem Abdelmohsen Abdelhakeem, Kalid Salah, Abdelrahman Mamdouh Saed
Parent Category: Year 2017, Volume 9
Category: Volume 9, Issue 7, July 2017
Background: Pneumonia is the leading cause of death in children. Few studies have explored the predictive value of copeptin in pediatric pneumonia.
Aim: This study aimed to assess the role of copeptin as a marker of severity of community-acquired pneumonia (CAP).
Methods: This prospective case-control study was carried out at Minia University Children’s Hospital in Minia (Egypt) from January to December 2016. Eighty children aged from 2 months to 42 months were enrolled in this study and were classified into group 1 (40 children with clinical, laboratory and radiological evidence of pneumonia) and group 2 (40 apparently healthy control). Serum copeptin level was assayed for all enrolled children.
Results: Mean serum copeptin level was significantly higher in pneumonic patients (985.7±619) pg/ml compared to controls (519±308.2) pg/ml (p<0.001). Serum copeptin was significantly elevated in survivors of pneumonia more than non-survivors (p=0.001). Also, copeptin was significantly higher in the group of non-survivors (1811.8±327.1) compared to 745.4±472.5 for survivors (p=0.01). There was a significant positive correlation between serum copeptin levels and the degree of respiratory distress (p=0.02).
Conclusion: Copeptin seems a reliable and available predictor marker for assessing the severity and prognosis of pediatric community acquired pneumonia.
Nike Air Max 2018Air Jordan 1 Retro High OG 'Rust Pink' 861428-101 For Sale
Keywords: Copeptin, Community acquired pneumonia, Outcome
Volume 12, Issue 4, October-December 2020
The worldwide spread of COVID-19 as an emerging, rapidly evolving situation, and the dramatic need of urgent medicine or vaccine, has rapidly brought new hypotheses for pathophysiology and potential medicinal agents to the fore. It is crucial that the research community provide a way to publish this research in a timely manner.
To contribute to this important public health discussion, the Electronic Physician Journal is excited to announce a fast-track procedure to help researchers publish their articles on COVID-19 related subjects that fall under the broad definition of public health, internal medicine, and pharmacology. We are especially welcome to all hypotheses about the pathological basis of the COVID-19 infection and the possible characteristics of potential medicine and vaccine. Submit your manuscript here
The 6th World Conference on Research Integrity (WCRI) is to be held on June 2-5, 2019 in Hong Kong.
The WCRI is the largest and most significant international conference on research integrity. Since the first conference in Lisbon in 2007, it has given researchers, teachers, funding agencies, government officials, journal editors, senior administrators, and research students opportunities to share experiences and to discuss and promote integrity in research. Read more:
TDR Clinical Research and Development Fellowships
Call for applications
Deadline for submission: 7 March 2019, 16:00 (GMT)
TDR provides fellowships for early- to mid-career researchers and clinical trial staff (e.g. clinicians, pharmacists, medical statisticians, data managers, other health researchers) in low- and middle-income countries (LMICs) to learn how to conduct clinical trials. Read more:
Meta-Analysis Workshops in New York, USA, and London, UK, in April and May 2019
Don't miss this exceptional opportunity to learn how to perform and report a Meta-analysis correctly. Two Meta-analysis workshops are organized in April and May 2019 by Dr. Michael Borenstein in New York, USA (April 08-10, 2019) and London, UK (May 27-29).
About the Instructor
Dr. Michael Borenstein, one of the authors of Introduction to Meta-Analysis, is widely recognized for his ability to make statistical concepts accessible to researchers as well as to statisticians. He has lectured widely on meta-analysis, including at the NIH, CDC, and FDA. Read more: